Podcast appearances and mentions of patrick short

Many people tell me they struggle to know what to say, on dates and in relationships. They worry about offending people or not being smart or interesting enough. Today's podcast guests, Patrick Short and Tiffany Crotty, have found a way to make communicating easier, and even more fun, and to help people be better. If you're not satisfied with your love or sex-life, and could use some insights into what makes women want more of you, tell me more about yourself here and we'll schedule a time to talk: shanajamescoaching.com/consult

Many people tell me they struggle to know what to say, on dates and in relationships. They worry about offending people or not being smart or interesting enough. Today's podcast guests, Patrick Short and Tiffany Crotty, have found a way to make communicating easier, and even more fun, and to help people be better. If you're not satisfied with your love or sex-life, and could use some insights into what makes women want more of you, tell me more about yourself here and we'll schedule a time to talk: shanajamescoaching.com/consult

MMC Principal, Charlotte Barttelot, leads our focus on data-driven health investments. In this episode, she interviews Patrick Short, founder and CEO of Sano Genetics - an MMC portfolio company that connects patients directly with biotech and pharmaceutical companies, accelerating research on rare and chronic diseases. The dramatic reduction of cost and time to sequence the human genome has led to the acceleration of personalised medicine. Charlotte and Patrick discuss the impact this has on the evolution of the drug development process, the change in attitude to the use of personal data, and how important the move towards greater trust and transparency in the industry is.

In this episode, Patrick welcomes J. Warren Huff, CEO and Chairman of Reata Pharmaceuticals. Reata is known for innovating small-molecule therapies for severe and life-threatening diseases. Listen in as Warren walks us through their approach of partnering with Universities to find scientific discoveries that could become the next generation of therapies, and Reata's recent success developing a groundbreaking new treatment for Friedreich's Ataxia (FA), thanks to close collaboration with patient organizations and novel use of natural history data to accelerate their clinical development. 0:00 The beginnings of Reata 2:40 Partnering with universities for breakthroughs in research 5:30 Implications of cancer prevention research on chronic diseases 11:40 Potential concerns in medical ethics and Big Pharma when developing groundbreaking treatments 13:20 Research on NRF2 and its role in treating Friedreich's Ataxia, a genetic mitochondrial disease that leads to motor neuron decline 18:00 What is a natural history study, and how was it used in Reata's FA clinical development? 22:50 The potential for clinical grade wearable devices 23:35 Determining clinical endpoints in clinical trials 26:00 The FDA's approval process for rare disease treatments 32:40 Potential for expanding newborn screening programs 36:00 The generalizability of NRF2-based research to other inflammatory diseases and diseases related to mitochondrial malfunction 39:40 What is Type 3 Diabetes? 40:30 Warren's career start as a lawyer and his journey to biotech 43:00 Searching for provocative biology 46:20 Major targets for the HSP program 48:30 Closing remarks and lessons in resiliency

Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare. Delve into the complexities of predicting disease, the challenges of screening programs, and the potential impact of integrating genomics into healthcare systems. Discover the limitations and potential of polygenic risk scores and gain valuable insights into the future of personalized medicine. 0:00 Intro 1:00 Clare's path to becoming a clinical geneticist and her research in uncovering genetic links to cancer 3:20 How do Polygenic Risk Scores help to predict disease, particularly breast cancer? 10:00 The influence of environmental and genetic effects on breast cancer presentation 11:30 Next clinical steps after determining genetic risk for breast cancer 17:30 How effective and accurate are polygenic risk scores in predicting various types of cancer, given the potential for false positives or negatives? 25:00 The potential for integrating genetic screenings and polygenic risk scores into early cancer diagnosis 27:20 How do monogenic risk scores like BRCA 1 and 2 fit into the paradigm of cancer research? 31:30 Using both monogenic and polygenic to explain population prevalence of disease 35:00 Integration of genomics and genetic screenings into the UK healthcare system 40:30 What comes after the genetic test? What is the use in identifying risk for a disease if nothing is subsequently done to prevent it? 44:50 Clare's upcoming work in remodeling NHS systems for evidence protocols and clinical use of genetic tests 46:50 Closing remarks

In this episode, Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera's approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing. 0:00 Intro 1:00 What prompted you to join Flagship Pioneering? 3:32 How is Flagship able to innovate and invent novel therapies in ways that Big Pharma companies may find difficult? 5:00 Introduction to gene writing and the role of Tessera Therapeutics 8:22 The current limitations and challenges of gene writing 10:22 Gene knockouts vs gene writing – which is more useful for genetic therapies? 12:30 Reasons why the liver the most commonly targeted organ for gene therapies 19:00 Lipid Nanoparticles and their role in gene writing 22:45 How do you guide mobile genetic elements to write genes in the intended location? 25:20 Development of gene writing technology since 2018 28:15 The implications of gene writing for diseases like PKU, Alpha-1 antitrypsin deficiency, sickle cell disease, and cancer 34:00 Next steps on the way to clinical trials 36:46 Using genomics and computational biology to guide measurable outcomes in drug discovery and development 40:15 Using gene writing to address rare developmental diseases 43:32 Closing remarks

0:00 Intro 0:45 The founding of BioTx.ai 4:35 How do algorithms for ‘causal inference' work? 6:30 Modeling gene interactions for genetic disorders 8:35 How to predict gene interactions 10:30 What happens after identifying a potential gene variant or interaction? 14:35 How can you use machine learning to determine causal relationships between gene variants and disease? 17:30 Deconvoluting genes and traits, and their impacts on effect size 19:20 Key ingredients in determining causal relationships: data and computational power 21:10 Limitations of using machine learning to find genetic determinants of rare diseases 24:30 Predicting clinical outcomes with Biotx.ai 28:05 Machine learning enhances efficiency in the pre-clinical phase 29:40 Population genomics in Germany 32:50 Marco's career decisions – starting a company vs. continuing in academia 35:50 The pros and cons of industry 38:10 The gaps in industry and academia 41:20 Closing remarks

Patrick Short, President, Peachtree Hospitality Management, says servant leadership is essential to hospitality success during The Hospitality Show. Here's why.

Join Patrick in welcoming Dr. Bettina Lundgren, CEO of the Danish National Genome Center. Bettina is spearheading the development of personalised medicine in Denmark with a focus on integrating genome sequencing directly into the healthcare system. She is dedicated to fostering international collaboration in research and healthcare delivery. Tune in to learn about the one of the leading national scale genomics initiatives, and Bettina's r insights on the future of personalised medicine! 0:00 Intro 0:56 Bettina's path to genomics 1:47 Aspirations of the Danish National Genome Center 4:18 Comparing the Danish National Genome Center to other global genomics programs 8:10 Goal to sequence 60,000 whole genomes by 2024 11:40 The biggest challenges of integrating genomics with healthcare 15:30 Navigating the politics of privacy and data sharing 20:02 Complexities of sharing data across diverse regions and healthcare systems 23:28 Partnerships across borders: Sweden, Europe, and the world 28:10 Looking forward 10 years: strategies and novel developments in personalised healthcare 31:25 Final Thoughts 32:37 Outro

In this milestone episode, we welcome Dr Matthew Hurles, geneticist and pioneer in the field of human genomics. Dr Hurles has dedicated his career to unravelling the secrets hidden within our DNA, as well as harnessing cutting-edge research to revolutionise our understanding of genetic disorders, human evolution, and the potential for personalised healthcare. Join Patrick and Matt as they delve into the frontiers of genomic science, from the implications of newborn screenings to emerging technologies and the transforming role of researchers. 0:00 Intro 1:55 Genetics in the '90s compared to genetics today 4:30 Work-life balance in science 8:00 Deciphering Developmental Disorders (DDD) study 13:10 New technologies in genome sequencing 14:45 How far are we from using next-generation sequencing as standard for diagnosing rare disease? 17:10 The Industrialization of genomics research 21:10 Will we move to a world where everyone is sequenced at birth? 25:20 Uses for cellular assays in healthcare and research 27:15 Bridging the gap between rare and common diseases 31:35 Birth cohorts and newborn screening studies 33:30 The power of early diagnosis and intervention with genomics 36:30 Open access databases 38:40 Advice for early-career researchers 41:20 Future directions for the Wellcome Sanger Institute 43:30 Applications of artificial intelligence and machine learning in genomics 45:30 Thank you 46:50 Outro

Join us for EP99 of The Genetics Podcast as Patrick dives into the extraordinary career and work of Dr. Harold E Varmus, a Nobel laureate scientist, former director of the National Institutes of Health, president of Memorial Sloan Kettering Cancer Centre, and director of the National Cancer Institute. Join Patrick and Harold as they navigate the complex landscape of cancer, from advancements that have revolutionized the field to diversity in cancer research and the Polyethnic-1000 Genome Project. This compelling episode is punctuated by Harold's personal reflections, and invaluable learnings from his career. 1:27 Why a Beowulf quote made its way into Harold's Nobel Prize acceptance speech 2:28 How it feels to hear you have won a Nobel Prize 4:04 How did fulfilling a national responsibility during the Vietnam War lead to a Nobel Prize 7:54 Areas of cancer research that are moving forward, and areas that are more stubborn 9:44 The formidable hurdle of metastasis 11:00 The educational power of COVID 12:33 Cancer and evolution: why is cancer so difficult? 14:50 Introducing the Polyethnic-1000 Genome Project 19:35 Working with WHO to ensure genomic technologies are accessible to all 23:03 What are the biggest blockers to the widespread adoption of genomics? 26:00 Context switching: From ‘deep' science to stepping into the role of director 28:50 Learnings on how science is funded and coordinated 33:05 Discussing the allocation of funding: small grants Vs. large, coordinated efforts 36:16 Co-founding PLoS and PubMed Central 39:49 Accelerating the shift towards more open science 44:44 Just how close are we to curing cancer? 48:00 Studying cancer rates in mammalian species

In this episode, Patrick is joined by Alex Cagan, a Postdoctoral Fellow in the Cancer, Ageing and Somatic Mutation programme at the Wellcome Sanger Institute, specialising in evolutionary processes in somatic tissue. Tune in as Alex walks us through a fascinating new study, years in the making, looking at somatic mutation rates across 16 mammalian species, spanning 30-fold in lifespan and around 40,000-fold in body mass. This work sheds light on fundamental questions in cancer and ageing across the tree of life. 0:00 Intro 6:00 Collaborating with the London Zoo, and the challenges of sourcing tissue from long-living animals 9:06 Why are naked mole rats so important to the cancer and ageing community? 11:32 The scale and breadth of species sampled in the study 14:53 Is there a ceiling to how many mutations an organism can tolerate? 17:53 Why are intestinal crypts so effective for sequencing somatic mutations? 20:44 Key learnings from driving a 5-year study into somatic evolution 22:46 Are there really any “immortal” species, and what are they? 25:19 Why are cancer rates lower in larger species, and is this related to lower mutation rates, DNA error correction or both? 27:24 Investigating transmissible cancers in Chernobyl 29:40 Is cancer everywhere in the tree of life? 31:23 Alex talks about applying his talent for illustration to science 38:56 The Sanger Tree of Life program, the Darwin Tree of Life project, and the bright future ahead for research on somatic mutations 40:14 Outro Find out more about the study: https://www.nature.com/articles/s41586-022-04618-z

In this episode, Patrick is joined by Cindy Lawley, Senior Director of Population Health at Olink Proteomics and co-host of the Proteomics in Proximity podcast. Cindy has worked with major population genomics programs, including the UK Biobank, to bring together proteomics, genomics, and deep phenotyping using the Olink platform. Olink is one of the most promising proteomics technologies on the market, and the platform has been used in >1,000 publications, including landmark work in the UKBiobank to integrate genomics and proteomics. The largest Olink assay currently covers around 3,000 proteins, and the scale continues to grow, while costs are decreasing, paving the way for larger integrated proteomic and genomic data sets in the future. Join Cindy and Patrick for this 45-minute episode as they explore: * how population-scale proteomics is driving novel discoveries * different proteomics technologies, cost and throughput trajectories, and what is on the horizon * surprising findings from longitudinal sampling of proteins And much more. If you would like to hear more from Cindy, listen to the Proteomics in Proximity podcast when you follow the link below. https://podfollow.com/1645900688

Food is medicine. And leveraging its power to heal isn't a new concept. In fact, roughly 50% of all small-molecule medicines are derived from nature. But what if we could use AI to better understand the biology of the millions of molecules humans already consume? What if we could then apply this information to identify new treatments for chronic diseases? This week, we're welcoming the CEO of Montai Health, Margo Georgiadis, to the podcast to discuss their AI platform that uses literature and wet lab experiments to analyse “the most privileged chemistry on Earth” to find new treatments for chronic diseases. Join Patrick and Margo for this hour-long episode, as they explore how Montai is leveraging technology to develop medicines based on the chemistry of food. From why ‘Anthromeolecules' represent an abundant source of opportunities for drug discovery to the potential for AI to accelerate drug discovery and healthcare, this jam-packed episode celebrates the intersection of nature and technology. After listening to this hour-long episode, you will: * understand Anthromolecules, and how the millions of molecules we already consume could be developed into new medicines * know how AI can be leveraged to build a ‘ChatGPT' to learn the language of biology and chemistry * recognise Margo's journey into biotech and healthcare, from her roots in the tech industry

Progress in AI is accelerating, and the potential in healthcare and precision medicine is enormous. In 2019, we had the pleasure of speaking with Dr Eric Topol, author of ‘The Patient Will See You Now' and ‘Deep Medicine'. Eric has had an incredible career which has been largely focused on researching cardiovascular disease and heart attacks, both of which he worked on in the Cleveland Clinic and Scripps Institute.  Now, we're reposting the interview as the conversation is more relevant than ever. Join Patrick and Eric as they discuss wireless medicine and the role of artificial intelligence and machine learning in medicine and healthcare.

“We're pioneering the ability to detect genetic disease earlier, and actually intervene in a way that is going to help those patients.” In this jam-packed 45-minute episode, we're joined by Dr Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals and Chair of the Founders Board for Our Future Health. Join Patrick and Paul as they expose the two major reasons that 90% of clinical drug development fails, and why many believe that embedding genetics into target discovery and validation can increase the success rate of trials by 2-5 times. They also deep-dive into: * the evolution of population genomics: from Iceland's DECODE to the UK Biobank * examples of the value of recontact-by-genotype studies in supporting safety studies for novel targets, evidenced by the recontact of an ultra-rare homozygous loss-of-function carrier of the gene HAO1 * the next chapter in population genomics that's pioneering the ability to detect genetic diseases earlier * the challenges of recontacting participants in biobanks and avoiding overwhelming the healthcare system, whilst responsibly handling patients' sensitive data * Alnylam's work to develop therapeutics for genetic diseases based on RNAi, the discovery that was awarded the Nobel Prize in Medicine or Physiology in 2006 Tune in to benefit from Paul's invaluable insights and expertise, which are coloured with practical examples from his career throughout. After listening to this 45 minute episode, you will: recognise the role of genetics in supporting the safety and efficacy of novel targets in clinical development understand the evolution of population genomics and what's next understand how RNAi works, and how it differs from gene editing and other forms of next-generation therapies

Access to genetic testing for patients with genetic diseases, such as ALS, can vary dramatically based on country and postcode. For an ALS patient considering genetic testing in Canada, the reality of their federally-funded healthcare system is a far cry from the general perception. In the US, genetic testing access and cost varies widely between community healthcare settings, and academic research centers. And in the UK, accessibility to genetic testing can be a simple matter of geography. In this webinar, Paul Wicks leads the discussion with Professor Ammar Al-Chalabi, Dr Patrick Short and Kristina Salmon on international perspectives on genetic testing for ALS. The lessons from this discussion apply not just to ALS, but the hundreds of other rare and common genetic diseases where access to genetic testing is a challenge for patients, healthcare providers, and researchers.

Access to genetic testing for patients with genetic diseases, such as ALS, can vary dramatically based on country and postcode. For an ALS patient considering genetic testing in Canada, the reality of their federally-funded healthcare system is a far cry from the general perception. In the US, genetic testing access and cost varies widely between community healthcare settings, and academic research centers. And in the UK, accessibility to genetic testing can be a simple matter of geography. In this webinar, Paul Wicks leads the discussion with Professor Ammar Al-Chalabi, Dr Patrick Short and Kristina Salmon on international perspectives on genetic testing for ALS. The lessons from this discussion apply not just to ALS, but the hundreds of other rare and common genetic diseases where access to genetic testing is a challenge for patients, healthcare providers, and researchers.

From changing drug pricing legislation to AI breakthroughs, in the first episode of The Genetics Podcast for 2023, Patrick makes four predictions for the biggest stories of 2023. We will check in at the end of the year to see how he did! For those interested in doing further reading, any resources mentioned during the podcast are linked below. https://www.wsj.com/articles/the-inflation-reduction-act-killing-potential-cures-pharmaceutical-companies-treatment-patients-drugs-prescriptions-ira-manufacturers-1166750829

If there's one genetics podcast episode to listen to this year, it's this one. In the final episode of The Genetics Podcast for 2022, we're joined by Dr Veera Rajagopal, who is known as the ‘GWAS storyteller' on Twitter for his prolific threads breaking down the latest findings in genetics. Join Patrick and Veera as they review the most exciting stories in genetics this year, from the impact the bubonic plague has had on human evolution and our modern day lives, to looking forward and celebrating more diverse, representative populations in genetics research. For those interested in doing further reading, Veera has kindly provided links to all the papers he references during this podcast episode, and we encourage you to follow him on Twitter @doctorveera and substack (https://gwasstories.substack.com/) for regular posts on the latest in genetics and genomics.

"If someone tells you it's not possible, then it's interesting" according to Treeway Chief Development Officer Ronald van der Geest. Founded in 2012 by two ALS patients who refuse to take their diagnoses lying down, Treeway develops novel treatments for ALS, Alzheimer's disease, and other neurodegenerative diseases. Join Patrick and Ronald in our latest podcast episode as they explore Treeway's roots, the four major disciplines required for successful development of novel treatments, discuss the landscape of ALS treatment options in 2022, and celebrate the power of a small group of people, smart design and resilience.

This week Patrick is joined by Baroness Nicola Blackwood, the first female MP for Oxford. She was elected by MPs of all parties to Chair the Commons Science and Technology Select Committee. Baroness Blackwood remains the youngest-ever select committee chair in British history and the only woman to have held that position. Nicola is chair of Genomics England and has been a champion for genomics and the life sciences in UK policy. This episode covers the past, present, and future of genomics in healthcare in the UK and some of the exciting initiatives on the horizon, including whole genome sequencing in newborn screening.

In this episode, guests Christine Ward, VP and Head of Oncology and Cell Therapy Precision & Translational Medicine at Takeda and Geoff Oxnard, Thoracic Oncologist and VP of Foundation Medicine talk to Patrick about Next Generation Sequencing (NGS) in precision oncology. Also covered are the impact of large-scale genetic datasets on patient diagnosis, data consortiums enabling pioneering discoveries, and the recent partnership between Takeda and Foundation Medicine.

This episode, our Partnerships Lead, Lindsey Wahlstrom-Edwards dove into the importance of representation in genetic research, covering the techniques used by leading organisations to make research more accessible and representative. Lindsey is joined by Listen to speakers Natasha Ratcliffe of COUCH Health, Del Smith of Acclinate and Ebony Scott of Lupus Research Alliance to learn how to make sure your precision medicine study is inclusive by design.

In this week's episode, GOLD speaks to Patrick Short, CEO, Sano Genetics, about the challenges and opportunities in genetic medicine today. He discusses his personal connection to tackling genetic diseases, the top reasons behind research participation hesitancy and the therapy areas in which he believes genomic testing and medicine could be most impactful. Plus, news from the World Health Summit. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Tackling the trust gap in genomic medicine https://www.emg-gold.com/post/tackling-the-trust-gap-in-genomic-medicine The rare disease disparity https://www.emg-gold.com/post/the-rare-disease-disparity Davidek Herron on embracing pharma's digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation

This week, Patrick speaks to Heidi Rehm who is at the top of the field of genome interpretation and medical genetics. She has been a pioneering figure in the curation and sharing of rare genomic datasets across a federated exchange known as The Genome Aggregation Database or gnomAD.

Dr Jessica Kissinger and her collaborators run some of the world's largest databases of multi-omic data from eukaryotic parasites. In this episode, we explore major findings in the field and Dr Kissinger's vision of large-scale interoperable datasets driving novel discoveries. Plus, Dr Kissinger shares her recent and personal experience of diagnosis with a rare disease, Ehlers-Danlos Syndrome, that puts everything into perspective.

Doctors have been transplanting organs for decades, but can we transplant reprogrammed stem cells to rejuvenate the human body? This week Patrick discusses transcriptional reprogramming, and bit.bio's opti-ox technology that has the potential to create every cell type and help kickstart a cell therapy revolution. With Mark Kotter Ph.D., neurosurgeon, and CEO and Founder of bit.bio.

About this Episode: This week's guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

This week's guest, Daniel MacArthur, is the Director of the Centre for Population Genomics at the Garvan Institute of Medical Research and Murdoch Children's Research Institute. Daniel and Patrick discuss the impact of large-scale genetic datasets on patient diagnosis and treating genetic subtypes of disease, the power of big data and consortiums to enable pioneering discoveries, and give advice for early career researchers thinking about the dichotomy between industry and academia.

This week Patrick is joined by Dietrich Stephan, Founder and CEO of NeuBase Therapeutics. They discuss how to overcome the challenges of 'un-druggable' diseases, how Neubase is cracking the druggable genome using its scalable technology, and how biotech companies are innovating to secure the investment needed to accelerate precision medicine during a challenging period for the industry.

From decoding the genetics of rare disease using computational methods, to understanding the non-coding and 'near-coding' genome, this week Patrick is joined by Nicky Whiffin, Group Leader at the Wellcome Centre for Human Genetics and Sir Henry Dale Fellow at the University of Oxford. They discuss what it's like to create a brand new research group and the potential impact of whole genome sequencing on diagnosis rates.

In this week's episode Patrick is joined by Michael Spigler, Vice President of Patient Support and Education at American Kidney Fund. They discuss how making genetic testing mainstream could significantly improve patient outcomes, why black Americans are four times more likely to experience chronic kidney failure, and what can be done to reduce the number of patients needing dialysis.

In this episode, Susannah and Sarah discuss the developments in technology and medical science and look deeper into the health sector. They speak to Dr Patrick Short, CEO of Sano Genetics, looking at the health sector from an investment perspective, as well as chatting to Sophie Lund-Yates about pharmaceutical companies and those serving the health sector. Also, Emma Wall talks to Olivia Micklem, a fund manager and analyst in Artemis' US equities team, about her health holdings.This podcast isn't personal advice. If you're not sure what's right for you seek advice. Investments rise and fall in value, so investors could make a loss. Hosted on Acast. See acast.com/privacy for more information.

This week Patrick is joined by Sir Peter Donnelly, CEO of Genomics PLC and Professor of Statistical Science at the University of Oxford. They discuss how to get from data to implementation in the clinic, the challenges of polygenic risk scores including prediction across different ethnic backgrounds, and the role of genomics in drug discovery.

This week's guest is Laurence Reid, CEO at Decibel Therapeutics. He talks to Patrick about the journey to deliver novel gene therapies to patients with genetic hearing loss and balance disorders, the future of tackling hearing issues at birth, and his experience learning about the field of inner-ear biology and taking up the role of CEO at Decibel.

This week Patrick is joined by three pioneering guests united by one ground-breaking project: the UK BioBank's Whole Genome Sequencing Project. Dr Mark Effingham, Deputy CEO of UK Biobank; Dr Kári Stefánsson, Founder and CEO of deCODE Genetics, and Professor Marylyn Ritchie, University of Pennsylvania, discuss the goals of the collaboration, it's challenges, and the potential it has to change the future of genomics research.

This week's guest is Nathalie Kingston, Director of the NIHR BioResource. She talks to Patrick about how the scale of the BioResource has grown dramatically over the last nine years, her most exciting moments as Director to date, and how the BioResource is using Sano's technology to accelerate and support its research programmes.

Defense attorney Patrick Short joins hosts Chris Spendlove and Ethan Scroggins to discuss his work and his journey. In this emotional interview, Patrick shares some of the experiences that have not only led him to this point in his career, but more importantly, that have shaped his worldview and outlook on life. Patrick reminds us that, as law students and lawyers, we have a unique opportunity to use our gifts to bless the lives of others. Keep honoring the gift!

In the last episode of the year, Patrick joins forces with the host of the Personalized Medicine Podcast, Oleksandr Yagensky, to discuss six of the biggest and most exciting breakthroughs in genetics research in 2021. They talk about developments including cancer testing in healthy people, newborn genetic screening, AI and machine learning, stem cells, and more.

Welcome to the final episode of 2021! This one was long in the making. We are happy to present the crossover episode between the Genetics Podcast and the Personalized Medicine Podcast. In this episode our host Oleksandr (Sasha) Yagensky wraps up 2021 with one and only Patrick Short, the CEO of Sano Genetics and host of the Genetics Podcast. Listen to Patrick and Sasha as they share their 2021 highlights from the world of Personalized Medicine.Together with Patrick we focused on 6 highlights in 2021: ◦ Large scale liquid biopsy trial for presymptomatic cancer detection ◦ Whole genome sequencing making its entry into newborn screening programs for rare diseases ◦ Advances in application of autologous iPSCs for treatment of Parkinson's disease ◦ Progress in one-time treatments to reverse genetic disorders ◦ Launch of the first FDA approved diagnostic test based on glycoprotein biomarkers for cancer detection ◦ Rise of AI in drug discovery & developmentListen and let us know if you agree with our list? Which important 2021 event did we miss? Let us know on our Twitter or LinkedIn channels.Make sure to check the Genetics Podcast. Patrick is a fantastic host and puts together great interviews with the thought-leaders in the fields of personalized medicine, rare diseases and genetics research.Download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this special episode we're sharing Patrick's guest appearance on GIANT's Healthy Innovators Podcast. He talks to the podcast's host, Barry Shrier, about the need to accelerate the development of new treatment options, how personalised medicine is changing the future of healthcare and what it takes to create a successful startup in the genomic medicine landscape.

In this special episode we're sharing Patrick's guest appearance on Genomics England's new podcast, The G Word. Patrick speaks to Chris Wigley, CEO of Genomics England, about his work on the Deciphering Developmental Disorders (DDD) project during his PhD and how his career has focused on the power of translation research to directly impact on and improve people's lives.

“It's a real power of some of the translational research that's being done that you can not only answer interesting, fundamental biological questions, but also impact people directly in the process.”  In this week's episode of The G Word, our CEO Chris Wigley is joined by Dr Patrick Short, genomic researcher, bioinformatician and Co-Founder and CEO of Sano Genetics. For his PhD Patrick worked on the Deciphering Developmental Disorders (DDD) project, with his findings and methods being used in Genomics England's 100k analysis, and he has designed and taught courses on machine learning and data science at Cambridge Spark.   Today Patrick talks about the human aspect of research, precision medicine research and industry access to data. He also discusses the Deciphering Developmental Disorders project and his work with Sano Genetics.  

This first episode of 2021 sees host Patrick Short talk to three insightful guests about their predictions for research and medicine in the year ahead. In this compilation episode, Patrick talks to Jane Theaker, Phillip Beer and Jason Mellad, each experts in their field. Our guests are: Jane Theaker, the CEO of Kinomica Limited, a company at the fore of precision medicine that's providing disruptive cell signalling technology. Jason Mellad, the CEO and Co-Founder of Start Codon a healthcare accelerator working to seed-fund truly disruptive healthcare start ups. Our final guest is Phillip Beer, a Physician scientist with expertise in clinical cancer genomics, early phase therapeutic development and biomarker discovery. Holds leadership roles in the commercial, healthcare and academic sectors.

Patrick Short served as the Executive Director of CSz Worldwide from 2002-2014, as well as President in 2019, and is a founding member of both CSz San Jose and CSz Portland. In this episode we dig into as many topics as Patrick has credentials, everything from the formation of the World Comedy League to the capacity for improvisation to elevate the human spirit.***The ComedySportz Podcast is an independent production made by CSz players. The views and opinions expressed by the podcast host and any guests are their own and do not represent the views and opinions of any CSz location or CSz Worldwide. Vocabulary used by the host and guests is not necessarily representative of the CSz brand.

Dr Patrick Short talks to Gemma Stunt about her son Bertie's diagnosis of Duchenne muscular dystrophy, how to get involved in clinical trials and what life is really like with a currently ‘incurable' genetic condition.

In this episode Patrick Short speaks with Allison Watson the co-founder and secretary of Ring20 Research and Support UK patient organisation and the co-chair of EpiCARE's patient advisory group. Allison discusses the Ring Chromosome 20 syndrome and the work of Ring20 Research and Support UK.

This episode was originally recorded for CUTalks, the podcast of the Cambridge University Technology & Enterprise club. In this podcast, CEO and Co-founder Dr Patrick Short discusses the personalised genomics industry, as well as his journey from PhD to founder and some important lessons he learnt along the way.

Dr Patrick Short answers the top genetic questions on quora. Which include:  1) How reliable is the DNA testing offered by sites like Ancestry.com or 23andMe? 2) Does DNA testing for diet and fitness really work? 3) Does 23andMe provide accurate results for people of Indian heritage? 4) How much of the genome does 23andMe sequence? Can their data be used to study disease? 5) How seriously would you take the DNA ancestry and health reports from a place like 23andMe?